Oxford BioMedica announces further capacity expansion with new facility
September 13, 2018 07:00 ET
|
Oxford BioMedica plc
Oxford BioMedica announces further capacity expansion with new facility Lentiviral vector bioprocessing market expected to grow to $800m by 2026Oxford BioMedica adds fourth facility in Oxford...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018
September 13, 2018 07:00 ET
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018 Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell...
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
August 28, 2018 07:00 ET
|
Oxford BioMedica plc
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and...
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
August 06, 2018 07:00 ET
|
Oxford BioMedica plc
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK –...
Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL
October 31, 2017 12:03 ET
|
Oxford BioMedica plc
Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL Oxford, UK - 31 October 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group")...
Oxford BioMedica plc: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017
August 17, 2017 07:00 ET
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017 Oxford, UK - 17 August 2017: Oxford BioMedica plc ("OXB" or "the Group"; LSE: OXB), a leading gene and cell therapy...
Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019
June 07, 2017 12:41 ET
|
Oxford BioMedica plc
Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs...